Alligator Bioscience
Total Raised
$10MInvestors Count
6Funding, Valuation & Revenue
5 Fundings
Alligator Bioscience has raised $10M over 5 rounds.
Alligator Bioscience's latest funding round was a IPO for on November 23, 2016.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/23/2016 | IPO | 1 | ||||
10/1/2015 | Unattributed VC - II | |||||
8/13/2015 | Unattributed VC | |||||
3/15/2010 | Seed VC | |||||
Other Investors |
Date | 11/23/2016 | 10/1/2015 | 8/13/2015 | 3/15/2010 | |
|---|---|---|---|---|---|
Round | IPO | Unattributed VC - II | Unattributed VC | Seed VC | Other Investors |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Alligator Bioscience Investors
6 Investors
Alligator Bioscience has 6 investors. Johnson & Johnson Innovation invested in Alligator Bioscience's Unattributed VC - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/13/2015 | 10/1/2015 | 2 Unattributed VC, Unattributed VC - II (2015) | Incubator/Accelerator | New Jersey | ||
Venture Capital | Denmark | |||||
Asset/Investment Management | Sweden | |||||
Venture Capital | Sweden | |||||
Venture Capital | Sweden |
First funding | 8/13/2015 | ||||
|---|---|---|---|---|---|
Last Funding | 10/1/2015 | ||||
Investor | |||||
Rounds | 2 Unattributed VC, Unattributed VC - II (2015) | ||||
Board Seats | |||||
Type | Incubator/Accelerator | Venture Capital | Asset/Investment Management | Venture Capital | Venture Capital |
Location | New Jersey | Denmark | Sweden | Sweden | Sweden |
Compare Alligator Bioscience to Competitors
NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.
PNP Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of cancer therapeutics. The company utilizes a platform technology for cancer treatment, including Gedeptin®. PNP Therapeutics is involved in licensing agreements, including a recent one with GeoVax, Inc. for its Gedeptin® intellectual property. It is based in Birmingham, Alabama.
Oxford Genome Sciences (UK) specialises in biotechnology focused on oncology and cancer detection. The company provides assay kits for cancer detection, cell biology tools, and polymerase chain reaction (PCR) technology to aid research and diagnostics in cancer. Their offerings also include glycosylation analysis and antibody development. It was founded in 2006 and is based in Abingdon, United Kingdom.
Humanetics is a clinical stage pharmaceutical company that works on solid tumor cancers and developing countermeasures for radiation exposure. The company creates radiation modulators intended to improve radiation treatments for cancer patients and protect normal tissues from radiation damage. Humanetics' primary product, BIO 300, is under development for use in oncology to sensitizing tumor cells to radiation, and for inflammatory lung diseases as a countermeasure for radiation exposure. It was founded in 1988 and is based in Minneapolis, Minnesota.
PlantForm Corporation is a biopharmaceutical company that develops and produces antibody and protein drugs within the biopharming industry. The company utilizes its vivoXPRESS platform for the production of biologic drugs. PlantForm's pipeline includes biosimilars of existing drugs, medical countermeasures for terrorism-related threats, and health programs for animals. It was founded in 2008 and is based in Toronto, Ontario.
Bexion Pharmaceuticals is a biotech company focused on developing treatments for oncology and central nervous system (CNS) disorders. The company is advancing its lead compound, BXQ-350, which is a modulator targeting S1P, through mid-stage clinical trials. It was founded in 2006 and is based in Covington, Kentucky.
Loading...